Prelude Capital Management’s Burning Rock Biotech BNR Stock Holding History

Prelude Capital Management’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,358	Closed	-$29.2K	–	1146
2023 Q2	$29.2K	Sell	1,358 -5,210	-79%	-$138K	﹤0.01%	998
2023 Q1	$185K	Buy	6,568 +3,289	+100%	+$98.5K	0.01%	878
2022 Q4	$73.8K	Sell	3,279 -8,863	-73%	-$202K	﹤0.01%	1109
2022 Q3	$290K	Buy	12,142 +6,442	+113%	+$208K	0.01%	885
2022 Q2	$166K	Buy	+5,700	New	+$255K	﹤0.01%	1332
2022 Q1	–	Sell	-1,250	Closed	-$119K	–	1847
2021 Q4	$119K	Hold	1,250	–	–	﹤0.01%	1683
2021 Q3	$224K	Sell	1,250 -66	-5%	-$14.7K	0.01%	1294
2021 Q2	$388K	Buy	1,316 +66	+5%	+$19.5K	0.01%	1077
2021 Q1	$337K	Buy	1,250 +190	+18%	+$57.8K	0.01%	1086
2020 Q4	$245K	Sell	1,060 -176	-14%	-$47.3K	0.01%	1014
2020 Q3	$310K	Buy	+1,236	New	+$293K	0.02%	546

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Prelude Capital Management's BNR Position: Q3 2023 in Review

Prelude Capital Management sold out of Burning Rock Biotech (BNR) in Q3 2023, closing a stake of 1,358 shares — an estimated $29.2K sold.

Prelude Capital Management first reported a position in BNR in Q3 2020 and held it in 11 quarters. The position peaked at $388K in Q2 2021. 28 funds tracked by Wall St. Rank hold BNR as of Q3 2023.

Prelude Capital Management reported no remaining Burning Rock Biotech position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 1,358 Burning Rock Biotech shares in Q3 2023, an estimated $29.2K.
Prelude Capital Management first reported a position in Burning Rock Biotech in Q3 2020 and held it in 11 quarters.
Prelude Capital Management's Burning Rock Biotech position peaked at $388K in Q2 2021.
28 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.